286 related articles for article (PubMed ID: 29945114)
1. Clinical and molecular aspects of breast cancer: Targets and therapies.
Godone RLN; Leitão GM; Araújo NB; Castelletti CHM; Lima-Filho JL; Martins DBG
Biomed Pharmacother; 2018 Oct; 106():14-34. PubMed ID: 29945114
[TBL] [Abstract][Full Text] [Related]
2. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
3. Impact of gene-expression profiling in patients with early breast cancer when applied outside the guideline directed indication area.
Schreuder K; Kuijer A; Rutgers EJT; Smorenburg CH; van Dalen T; Siesling S
Eur J Cancer; 2017 Oct; 84():270-277. PubMed ID: 28844015
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
5. The Evolving Landscape of HER2 Targeting in Breast Cancer.
Moasser MM; Krop IE
JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261
[TBL] [Abstract][Full Text] [Related]
6. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies.
Matsuoka T; Yashiro M
World J Gastroenterol; 2016 Jan; 22(2):776-89. PubMed ID: 26811624
[TBL] [Abstract][Full Text] [Related]
7. Potential Novel Therapy Targets in Neuroendocrine Carcinomas of the Breast.
Vranic S; Palazzo J; Sanati S; Florento E; Contreras E; Xiu J; Swensen J; Gatalica Z
Clin Breast Cancer; 2019 Apr; 19(2):131-136. PubMed ID: 30268765
[TBL] [Abstract][Full Text] [Related]
8. Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
Toss A; Venturelli M; Peterle C; Piacentini F; Cascinu S; Cortesi L
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28054957
[TBL] [Abstract][Full Text] [Related]
9. The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.
Jiang X; Pissaloux D; De La Fouchardiere C; Desseigne F; Wang Q; Attignon V; Fondrevelle ME; De La Fouchardiere A; Perol M; Cassier P; Seigne C; Perol D; Ray-Coquard I; Meeus P; Fayette J; Flechon A; Le Cesne A; Penel N; Tredan O; Blay JY
Oncotarget; 2015 Sep; 6(28):26388-99. PubMed ID: 26317543
[TBL] [Abstract][Full Text] [Related]
10. Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.
Birnbaum DJ; Bertucci F; Finetti P; Birnbaum D; Mamessier E
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):248-255. PubMed ID: 29499330
[TBL] [Abstract][Full Text] [Related]
11. Precision Medicine and Targeted Therapies in Breast Cancer.
Greenwalt I; Zaza N; Das S; Li BD
Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
[TBL] [Abstract][Full Text] [Related]
12. Companion diagnostics for the targeted therapy of gastric cancer.
Yoo C; Park YS
World J Gastroenterol; 2015 Oct; 21(39):10948-55. PubMed ID: 26494953
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
14. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
El Hage Chehade H; Wazir U; Mokbel K; Kasem A; Mokbel K
Am J Surg; 2018 Jan; 215(1):171-178. PubMed ID: 28622841
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic Predictors of Response.
Hertz DL; Rae JM
Adv Exp Med Biol; 2016; 882():191-215. PubMed ID: 26987536
[TBL] [Abstract][Full Text] [Related]
16. Gene profiling assay and application: the predictive role in primary therapy.
Fumagalli D; Desmedt C; Ignatiadis M; Loi S; Piccart M; Sotiriou C
J Natl Cancer Inst Monogr; 2011; 2011(43):124-7. PubMed ID: 22043058
[TBL] [Abstract][Full Text] [Related]
17. Precision and predictive medicine in urothelial cancer: are we making progress?
Bellmunt J; Orsola A; Sonpavde G
Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
19. How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.
Farwell MD; Clark AS; Mankoff DA
JAMA Oncol; 2015 Jul; 1(4):421-2. PubMed ID: 26181243
[No Abstract] [Full Text] [Related]
20. Precision medicine in breast cancer: From clinical trials to clinical practice.
Crimini E; Repetto M; Aftimos P; Botticelli A; Marchetti P; Curigliano G
Cancer Treat Rev; 2021 Jul; 98():102223. PubMed ID: 34049187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
